Odyssey Therapeutics (NASDAQ: ODTX) recently received a number of ratings updates from brokerages and research firms:
- 8/27/2026 – Odyssey Therapeutics is now covered by HC Wainwright. They set a “buy” rating and a $44.00 price target on the stock.
- 8/27/2026 – Odyssey Therapeutics was upgraded by HC Wainwright to “strong-buy”.
- 8/11/2026 – Odyssey Therapeutics is now covered by Weiss Ratings. They set a “sell (d+)” rating on the stock.
- 8/7/2026 – Odyssey Therapeutics had its price target raised by JPMorgan Chase & Co. from $26.00 to $29.00. They now have an “overweight” rating on the stock.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc is based in BOSTON.
Featured Articles
- Five stocks we like better than Odyssey Therapeutics
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
- BWX Technologies’ Army Reactor Win Could Redraw Its Nuclear Growth Story
Receive News & Ratings for Odyssey Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odyssey Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
